This innovative AI-enabled tool empowers clinicians to make faster, more informed decisions by seamlessly integrating advanced image processing and diagnostic pathology data with medical imaging. Designed to deliver a comprehensive, cost-effective breast cancer recurrence risk profile, it integrates effortlessly into clinical workflows, supporting timely and accurate care decisions. TumorSight Risk provides a powerful digital test result that augments traditional gene expression tests, enabling clinicians to guide patients with confidence.
*This device is not FDA cleared or approved
TumorSight Risk combines imaging data with standard pathology data to:
Assess breast cancer recurrence risk within 5 years of diagnosis.
Generate a numerical score and categorize patients as "High Risk" or "Low Risk."
This A.I. driven solution eliminates the need for additional tissue samples, using non-destructive imaging techniques to deliver precise, consistent results.
Dynamic Contrast Enhanced
HER2, HR, Histology, Staging, Grade
Age, Race
©SimBioSys
